Ishizuka M, Takeuchi T, Masuda T, Fukasawa S, Umezawa H
J Antibiot (Tokyo). 1981 Mar;34(3):331-40. doi: 10.7164/antibiotics.34.331.
Antitumor antibiotics were examined as possible candidates that possess activity which inhibits preferentially suppressor cells in comparison with effector cells. In screening for such compounds among known antibiotics, aclacinomycin was found to augment antibody formation and delayed-type hypersensitivity in mice over a wide concentration range. The addition of aclacinomycin to mouse spleen cell cultures also enhanced antibody formation in vitro. The generation of suppressor cells or the suppressor activity per se in mice immunized with high doses of SRBC was reduced by aclacinomycin. These results suggest that the drug may possibly inhibit suppressor cells selectively. The administration of aclacinomycin at ow doses exhibited antitumor effects on IMC carcinoma; the effect was not dose-dependent.
对抗肿瘤抗生素进行了研究，以寻找那些与效应细胞相比，优先抑制抑制细胞活性的可能候选药物。在已知抗生素中筛选此类化合物时，发现阿克拉霉素在很宽的浓度范围内可增强小鼠的抗体形成和迟发型超敏反应。将阿克拉霉素添加到小鼠脾细胞培养物中也能增强体外抗体形成。阿克拉霉素可减少用高剂量绵羊红细胞免疫的小鼠中抑制细胞的产生或抑制活性本身。这些结果表明该药物可能选择性地抑制抑制细胞。低剂量给予阿克拉霉素对IMC癌显示出抗肿瘤作用；该作用不依赖剂量。
